Trial site
Neurocor Banaszkiewicz Tomaszewski Lekarze sp.p.
Cracow, 31-870, PolandEU-13 widening countryNot linked to an institution yet
- 9running trials
- 1closed trial
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 22 trials
- Phase 1/21 trial
- Status
- Active, not recruiting4 trials
- Recruiting4 trials
- Completed1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Merz Therapeutics GmbH2 trials
- UCB Biopharma SRL2 trials
- Aurinia Pharmaceuticals Inc.1 trial
- Grifols Therapeutics LLC1 trial
- NMD Pharma A/S1 trial
- and 3 more
Running trials
Recruiting
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289· Phase 3· UCB Biopharma SRL· Source
Recruiting
A Phase III study to evaluate how the body processes Xembify in comparison to Gamunex-C and determine the safety and in people with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
2025-522165-30-00· Phase 3· Grifols Therapeutics LLC· Source
Recruiting
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis
2025-525127-27-00· Phase 1/2· Aurinia Pharmaceuticals Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521· Phase 3· UCB Biopharma SRL· Source
Active, not recruiting
A Phase 3b open-label, randomised study of IPX203 in subjects with advanced Parkinson’s disease and motor fluctuations - ADIP study
2025-521772-57-00· Phase 3· Zambon Biotech S.A.· Source
Active, not recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713· Phase 3· Merz Therapeutics GmbH· Source
Active, not recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700· Phase 3· Merz Therapeutics GmbH· Source
Active, not recruiting
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
2023-507539-40-00· Phase 2· NMD Pharma A/S· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error